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Abstract 
Background: Multicentre trials investigating food allergies by double blind placebo controlled food challenges (DBP‑
CFC) need standardized procedures, challenge meals and evaluation criteria. We aimed at developing a standardized 
approach for identifying patients with birch related soy allergy by means of DBPCFC to soy, including determination 
of threshold levels, in a multicentre setting.
Methods: Microbiologically stable soy challenge meals were composed of protein isolate with consistent Gly m 4 
levels. Patients sensitized to main birch allergen Bet v 1 and concomitant sensitization to its soy homologue Gly m 4 
underwent DBPCFC. Outcome was defined according to presence and/or absence of ten objective signs and intensity 
of eight subjective symptoms as measured by visual analogue scale (VAS).
Results: 138 adult subjects (63.8% female, mean age 38 years) underwent DBPCFC. Challenge meals and defined 
evaluation criteria showed good applicability in all centres involved. 45.7% presented with objective signs and 65.2% 
with subjective symptoms at soy challenge. Placebo challenge meals elicited non‑cardiovascular objective signs in 
11.6%. In 82 (59.4%) subjects DBPCFC was judged as positive. 70.7% of DPBCFC+ showed objective signs and 85.4% 
subjective symptoms at soy challenge. Subjective symptoms to soy challenge meal in DBPCFC+ subjects started at 
significantly lower dose levels than objective signs (p < 0.001). Median cumulative eliciting doses for first objective 
signs in DBPCFC+ subjects were 4.7 g [0.7–24.7] and 0.7 g [0.2–4.7] total soy protein for first subjective symptoms 
(p = 0.01).
Conclusions: We present the hitherto largest group of adults with Bet v 1 and Gly m 4 sensitization being investi‑
gated by DBPCFC. In this type of food allergy evaluation of DBPCFC outcome should not only include monitoring of 
objective signs but also scoring of subjective symptoms. Our data may contribute to standardize DBPCFC in pollen‑
related food allergy in multicentre settings.
Trial registration: EudraCT: 2009‑011737‑27.
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Background
There is still debate whether allergen-specific immu-
notherapy (AIT) with birch pollen improves birch pol-
len-related food allergy [1, 2]. One reason for partly 
contradictory data of previous trials on this topic is the 
lack of standardized tests to assess clinical reactions 
to birch pollen-related foods [1, 2]. Double blind pla-
cebo controlled food challenge (DBPCFC) is considered 
as gold standard in diagnosis of food allergy [3]. When 
performing DBPCFC within multicentre trials, there 
is a need for standardization of challenge meals (CM), 
procedures and evaluation criteria [4–8]. In 2012, the 
PRACTALL group published a proposal for DBPCFC 
standardization [7], but interpretation of results still 
mainly depends on the investigator’s judgment [9]. The 
definition of relevant and comprehensive cut off values 
for subjective [10, 11] as well as for objective signs is chal-
lenging and differences between observers in interpreting 
DBPCFCs have been shown [12]. Another major problem 
is the interpretation of symptoms to placebo meals [10]. 
There exist only few published data on the frequency and 
type of those placebo reactions [13–15].
With regard to growing numbers of patients with birch 
pollen-related soy allergy, partly with severe reactions 
[16–19], we aimed at identifying subjects with birch 
pollen-related soy allergy by DBPCFC. Here we present 
a standardized approach for DBPCFC with newly devel-
oped challenge meals and evaluation scores that were 
set up for a multicentre trial. In contrast to challenge 
meals having been applied in other trials on birch pollen-
related food allergies, i.e. to apple or hazelnut [20, 21], we 
expected best possible standardization of challenge meals 
due to the availability of purified soy proteins [22]. In a 
follow-up investigation patients with birch pollen-related 
soy allergy were to be included in a trial investigating any 
effect of birch pollen AIT on this type of food allergy [1].
Methods
Setting and patient selection
Between January 2010 and February 2013, birch allergic 
adults (18–65 years) were recruited in 16 centres (15 Ger-
man, one Swiss). They underwent standardized allergy 
interview, skin prick test (SPT) with a panel of frequent 
respiratory allergens including birch (Allergopharma 
GmbH & Co KG, Reinbek, Germany) and serum IgE test 
for Bet v 1 and Gly m 4 (ThermoFisher, Freiburg, Ger-
many). Eligibility for DBPCFC was defined at presence of 
≥3.5  kU/l of specific IgE for birch allergen Bet v 1 and 
≥0.7 kU/l for its soy homologue Gly m 4. Pre-challenge 
assessments ensured no interference of acute or chronic 
diseases or drugs. DBPCFC was preferentially performed 
in the morning to exclude as far as possible confound-
ing factors as heavy meals (a light, allergen free breakfast 
was allowed) as well as physical or psychological stress. 
The trial (EudraCT: 2009-011737-27) was approved by 
the central ethical committee at Universität Leipzig, Ger-
many (No. 230-09-ff-09112009), the local German boards 
and the local ethical committee Zurich (KEK-2010-0039). 
All patients gave written informed consent.
Challenge meal and DBPCFC
Soy and placebo CM consisted of soy free cocoa, carob 
flour, oat flakes, rice flour, and sugar. Nine doses of iso-
lated soy powder Supro®760IP (88% protein, 12% ash, 
moisture, fat; Uelzena, Uelzen, Germany) were included 
in soy-containing CM. Single dose levels of soy protein 
were 0.0004–0.0044–0.05–0.15–0.5–1.5–2.5–5–15  g; 
resulting in a maximum cumulative dose 24.7  g protein 
(28.1 g powder). Placebo-CM also contained Sinlac® (rice 
flour, carob flour, saccharose; Nestlé Nutrition GmbH, 
Frankfurt, Germany). Five volunteers without known type 
1 sensitization to birch or soy participated in triangle test 
[4] to investigate any sensory differences between soy and 
placebo meals. For further validation of CM, patients were 
asked to guess wether they had received active or placebo 
meal at the last dose level applied. As patients with clini-
cal reactions rather would suspect to have had active CM, 
we only considered those patients with negative outcome 
of DBPCFC. Trial sites prepared meals freshly by adding 
defined amounts of tap water to centrally produced pow-
dered meals (Pharmacy of the University Hospital, Leip-
zig, Germany). At weeks 0, 6 and 12, all batches of soy 
meals (levels 4/9), and at week 0, all batches of placebo 
meals (level 9) and of soy protein isolate were analysed for 
Gly m 4 contents [22] as well as for microbiological con-
taminations (Institute of Laboratory medicine, Clinical 
chemistry and Molecular diagnostics, University Hospi-
tal, Leipzig, Germany). DBPCFC was performed on two 
separate days outside of birch pollen season (randomized 
sequence of soy and placebo meals). Meals were kept 
for several seconds in the oral cavity before swallowing. 
Increasing dose levels were applied at 20 min intervals.
Evaluation of signs and symptoms
At two meetings, investigators were trained for docu-
mentation of ten objective (O) signs (O1-intraoral 
swelling/blistering, O2-flush, O3-urticaria, O4-angi-
oedema, O5-conjunctivitis, O6-rhinitis, O7-peak 
flow reduction (PEFR)  >  20%, O8-drop of blood pres-
sure (BPD)  >  20  mmHg, O9-increase of heart rate 
(HRI) > 20%, O10-diarrhea/vomiting). Patients recorded 
subjective (S) symptoms (S1—enoral tingling/itching, 
S2—perceived lip swelling, S3—itching skin/eye/nose, 
S4—dysphagia, S5—dyspnea, S6—nausea, S7—abdomi-
nal pain, S8—dizziness) on 10 cm visual analogue scales 
(VAS) [23, 24]. Scales were anchored by the terms “not 
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present”/very strong” at the left/right end of the scale 
meaning higher scores indicate greater symptom inten-
sity. They were provided with descriptions of subjective 
symptoms as follows (original in German): S1—I have 
tingling or scratching or a furry feeling in my throat, S2—
My mouth and/or my lips feel big and swollen, S3—I feel 
itching/tingling/scratching (skin, eyes, nose, ears, hands, 
feet), S4 I feel constriction, pressure, swelling or lump in 
my throat, S5—I find it difficult to breathe deeply, S6—I 
feel sick/nauseated, S7—I feel bloated, heartburn, stom-
ach ache, stomach pain. I have the gripes, S8—I feel dizzy.
Fully blinded investigators followed calculation/classifi-
cation procedures and assessments of reactions indepen-
dently from application of soy or placebo CM.
DBPCFC had to be stopped (i) at dose level 9, (ii) at 
occurrence of definite objective signs or (iii) on patient’s 
demand. Lowest observed adverse effect level (LOAEL), 
and median cumulative threshold dose (MCTD) were 
determined in the study population with positive DBP-
CFC. A positive reaction to soy or placebo meal was 
defined if a patient presented at least one of the following 
three reaction types:
Objective type—an objective sign as defined (01–10) 
and/or
Single subjective type—at least a single subjective 
symptom as defined (S1–S8) with VAS value reaching 
1.5 cm or more and/or
Subjective sum type—two or more subjective symp-
toms (S1–S8) with single VAS values each reaching 
0.5  cm or more and summing up to 4 cm or more in 
total.
Any objective sign or subjective symptom occurring 
at placebo meal was classified as either minor or major. 
Only major placebo reactions (MPR) were taken into 
account when defining outcome of DBPCFC as positive 
(+) or negative (−) (including patients with major pla-
cebo reactions, Fig.  1). Criteria of MPR were fulfilled, 
when the intensity of objective signs or subjective symp-
toms to placebo exceeded those to soy meal (Table 1).
Serology
All subjects were investigated for total IgE and sIgE 
against Bet v 1 and Gly m 4 (ThermoFisher, Freiburg, 
Germany) before DBPCFC. 56/82 DBPCFC+ patients 
being eligible for AIT were further investigated for sIgE 
against Bet v 2, Gly m 5 and Gly m 6 (ThermoFisher).
Statistics
Between-group comparisons of DBPCFC+ and DBP-
CFC− patients were performed descriptively by exact 
Fisher’s test and Mann–Whitney U test depending on 
the scale and distribution (binary or ordinal/skewed) 
of DBPCFC characteristics after soy challenge. In DBP-
CFC+ patients, symptom characteristics after soy and 
SubjS 
Soy meal 
DBPCFC - ObjS 
ObjS major 
(MPR) 
ObjS major 
(MPR) SubjS 
DBPCFC - DBPCFC + DBPCFC - DBPCFC - 
Placebo meal Placebo meal 
or
SubjS 
ObjS SubjS 
no 
no 
no no no 
yes yes 
yes 
yes yes 
yes 
Fig. 1 Flow chart for determination of DBPCFC outcome. +, positive; −, negative; ObjS, objective signs; SubjS, subjective symptoms. For definition 
of major placebo reaction see Table 1
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placebo challenge were compared by McNemar test and 
Wilcoxon paired rang sum tests. P-values  <  0.05 were 
considered as statistically significant. No adjustment for 
multiple tests was performed since the aspects investi-
gated primarily served as additional data description.
Results
Challenge meals
Triangle tests revealed no significant perceivable differ-
ences between soy and placebo CM.
56 patients with negative DBPCFC gave their assump-
tion whether they had received soy or placebo CM. At 
soy CM (data available for n = 48), 14/48 (29% [95% con-
fidence interval/CI:18; 43]) correctly suspected soy and 
34/48 (71% [57; 82]) falsely suspected placebo CM. At pla-
cebo CM (data available for n = 45), 18/45 (60% [45; 73]) 
falsely suspected soy and 27/45 (73% [27; 55]) correctly 
suspected placebo CM. Overlapping CI between false as 
well as between correct guesses for placebo and soy indi-
cated no significant differences between both CM.
Quantification of Gly m 4 levels (aggregated over all 
batches) gave
0.012610% (CI 0.011741; 0.013478%.) in pure soy 
Supro®760IP;
0.000410% (CI 0.000386; 0.000434) in dose level 4 and
0.002164% (CI 0.002051; 0.002278) in dose level 9.
Coefficients of variation at or below 20% were found 
for the predefined shelf life of 12  weeks in all series 
measured. No Gly m 4 was-detectable in any placebo 
batch with respect to the detection limit of the ELISA 
used [22]. No significant microbiological impurities 
were detected in any batch within these 12 weeks. Prep-
aration and application of CM was easy to handle in all 
centres.
Study population
195 patients (63.6% female, mean (standard deviation) 
38.1 (12.8) years) were screened, 193 (95.6%) had posi-
tive SPT to birch. 80 (41%) reported on previous symp-
toms upon consumption of soy containing foods, which 
were mostly of mild character. 138 (63.8% female, 38 
(12.6) years) underwent DBPCFC (276 challenges). 82 
(59.4%) fulfilled the criteria of positive DBPCFC (62.2% 
female, 37.0 (13.6) years. 81 (98.8%) DBPCFC+ subjects 
had allergic rhinitis, 41 (50%) allergic asthma, 26 (31.7%) 
atopic eczema.
Evaluation of DBPCFC
Maximum dose 9 was applied in 104/138 (75.4% [95%-CI: 
67.6; 81.8]) at soy and in 125 (90.6 [84.5; 94.4] %) at pla-
cebo challenge (significant differences). Objective signs 
occurred in 63 (45.6 [38.3; 54.7] %) at soy as well as in 
30 (21.7 [13.8; 27.0] %) at placebo challenge (statistically 
Table 1 Definitions of major placebo reactions (MPR) at DBPCFC with examples
ObjS objective signs, SubjS subjective symptoms, VASsoy/VASplacebo visual analogue scale value at soy/placebo challenge in cm
* Single VAS of at least 1.5 cm
** Single VAS of at least 0.5 cm
*** Sum of VAS values of at least 0.5 cm, e.g.—example given
Type of major placebo 
reaction (MPR)
Definition according to signs or symp-
toms elicited by placebo challenge 
meal
Example for reaction elicited by pla-
cebo challenge meal Dose level/VAS-
placebo
Example for reaction elicited by
Soy challenge meal
Dose level/VAS
Objective Any ObjS (O1‑10, attributable to the 
DBPCFC)
Any Any or none
Any ObjS (O1‑10, not clear if being attrib‑
utable to the DBPCFC
i.e. single wheal) at a lower dose level 
compared to soy
5 or below 6
Subjective Any single SubjS* (S1–8) at lower dose 
level compared to soy
5 or below/any VASplacebo * 6/any VASsoy *
Single* Any single SubjS* (S1–8) at same dose 
level like any single SubjS* to soy
5/any VASplacebo * 5/any VASsoy *
Single** Any single SubjS** (S1–8) at same dose 
level like any single SubjS to soy and no 
difference of at least 2 cm in favor of soy
4/any VASplacebo **
(e.g. 0.6 cm)
4/any VASsoy ***
< VAS*** placebo ‑2 cm
(e.g. 2 cm)
Sum type*** Two or more aggregated SubjS** (S1–10) 
and two or more aggregated SubjS** 
(S1–8) to soy (any but same dose level 
for both)
and no difference between sum VAS val‑
ues of at least 2 cm in favor of soy
5/any sum VASplacebo ***
(e.g. 4 cm)
5/any sum VASsoy ***
< sum VASplacebo ***‑2 cm
(e.g. 5 cm)
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significant). Median lowest dose [IQR] which induced 
objective signs was dose 6 [4–7] at soy and 5 [3–7] at pla-
cebo challenge.
Subjective symptoms occurred in 90 (65.2 [95%-CI: 
57.0; 72.7] %) at soy as well as in 57 (41.3 [33.4; 49.6] %) 
at placebo challenge (statistically significant). Single sub-
jective type symptoms were observed in all patients with 
subjective reactions while sum type subjective symp-
toms occurred in 72 (52.2 [43.9; 60.3] %) to soy and 46 
(33.3 [26.0; 41.6] %) to placebo (statistically significant). 
Median lowest dose [IQR] which induced subjective 
symptoms was dose 5 for both soy and placebo [3–6 
and 2–7; respectively]. All objective signs and subjective 
symptoms were predominantly of the mucocutaneous 
type (Figs. 2 and 3).
In 82/138 (59%) subjects, DBPCFC was judged as 
positive. Detailed data on objective signs and subjec-
tive symptoms in DBPCFC+ and DBPCFC− subjects 
as well as numbers of major placebo reactions are given 
in Table  2. Subjective placebo reactions (single and/or 
sum values) were reported by 41% (n  =  57). Charac-
teristics of objective signs and subjective symptoms of 
DBPCFC+ and DBPCFC− subjects are given in Fig.  2 
and 3. Significant differences between DBPCFC+ and 
DBPCFC− patients were demonstrated with regard to 
occurrence of objective signs and subjective symptoms 
(Table 2).
Characteristics of patients with positive DBPCFC
58/82 DBPCFC+ subjects (70.7 [95%-CI: 61; 80]%) 
showed objective signs and 70 (85.4.4 [76.1; 91.4]%) sub-
jective symptoms at soy challenge (Figs.  2, 3). 11 (13.4. 
[7.7; 22.4]%) DBPCFC+ subjects had objective signs and 
26 (31.7 [22.6; 42.4]%) subjective symptoms at placebo 
challenge. The majority of objective signs caused by soy 
CM were of the mucocutaneous type (Fig. 2). No objec-
tive signs occurred in 24 (29.2%) subjects at soy CM and 
in 71 (86.6%) at placebo CM.
Ten (12.2%) of DBPCFC+ subjects patients reported 
MPR of subjective type to placebo (Table  2) but all of 
them had more extended objective signs to soy.
In DBPCFC+ patients, median single/maximum VAS 
values [IQR] at lowest dose of occurrence were 2.2  cm 
[1.6–3.3] at soy and 0 cm [0–1.6] at placebo challenge. In 
contrast, in DBPCFC− subjects, VAS values were 0  cm 
[0–1.7] at soy and 1.5 cm [0–2.3] at placebo challenge.
Subjective symptoms at soy challenge started mostly at 
lower dose levels (median dose 5 [IQR 3–6]) than objec-
tive signs (median dose 6; [4–7]) (p = 0.01; Fig. 3).
MCTD [IQR] for first objective signs was 4.7  g [0.7–
24.7] and for first subjective symptoms 0.7  g (0.2–4.7) 
soy protein (p = 0.01). Cumulative threshold doses of soy 
protein eliciting objective signs or subjective symptoms 
in 50% of subjects (ED50) can be extrapolated from Fig. 4. 
Four DBPCFC+ patients showed subjective symptoms 
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Fig. 2 Objective signs at lowest objective sign dose to soy and to placebo challenge meals. 138 subjects underwent DBPCFC, 82/138 were DBPCFC 
+. At soy challenge, 51/138 (24/82 DBPCFC+) patients had no objective signs and 9/82 DBPCFC+ presented with more than one sign. At placebo 
challenge, 71/138 (71/82 DBPCFC+) had no objective signs. Urt, urticaria; AED, angioedema; PEFR, peak flow reduction > 20%; BPD, drop of blood 
pressure > 20 mmHg; HRI, heart rate increase > 20%; GIT, gastrointestinal symptoms
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and two objective signs at first dose level which therefore 
corresponded to LOAELs.
Serology
In 138 patients with DBPCFC, total IgE (median [IQR]) 
was 165  kU/l [87.4–417], sIgE against Bet v 1 34  kU/l 
[17.3–68.7] and against Gly m 4 8.3  kU/l [0.8–3.8]. In 
DBPCFC+, sIgE against Bet v 1 was 34 kU/l [17.3–68.7] 
versus 35.6 kU/l [16.9–60] in DBPCFC− and against Gly 
m 4 8.3 kU/l [3.8–16.2] vs. 5.67 kU/l [2.8–17.03], respec-
tively (n.s.). Further sIgE in 56/82 DBPCFC+, rand-
omized for AIT, was positive against Bet v 2 in 9/56 and 
low level sIgE was found against both Gly m 5 and Gly m 
5 in only 1/56 patients.
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Fig. 3 Subjective symptoms at lowest subjective symptom dose to soy and to placebo challenge meals. 138 subjects underwent DBPCFC, 82/138 
wereDBPCFC+. Intraoral, tingling/itching; lip, swelling; itch, skin/eye/nose; abd., abdominal
Table 2 Characteristics of DBPCFC positive and DBPCFC negative subjects
Maximum dose levels applied and occurrence of objective signs, subjective symptoms and major placebo reactions in DBPCFC positive and DBPCFC negative patients 
at soy and placebo challenge meals. 95% confidence intervals are given (per cent based on the number of patients per group; in case of non-overlapping confidence 
intervals significant differences with α = 5% between populations exist)
n.s. not significant
a For definition of Major placebo reactions see Table 1
DBPCFC
negative (n)
DBPCFC
positive (n)
differences with
α = 5% between groups
Number of subjects 56 (40.6%) 82 (59.4%)
Maximum soy challenge meal level 9 applied 53 (94.6% [85.4; 98.2]) 51 (62.2% [51.4; 71.9]) Significant
Maximum placebo challenge meal level 9 applied 48
(85.7%[74.3; 92.6])
77
(93.9% [86.5; 97.4])
n.s.
Objective signs (O1‑10) at soy challenge meal
(in n patients)
5
(8.9% [3.9; 19.3])
58
(70.7% [61.4; 80.5])
Significant
Subjective symptoms (S1–8) at soy challenge meal
(single type or sum type)
20
(35.7% [24.5; 48.8])
70
(85.4% [76.1; 91.4])
Significant
Major placebo reactions objective typea 19
(33.9% [24.5; 48.8])
0
(0% [0; 4.5])
Significant
Major placebo reactions subjective typea 27
(48.2% [35.7; 61.0])
10
(12.2% [6.8; 21.0])
Significant
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Discussion
Here we present the hitherto largest group of adults with 
combined sensitization to birch allergen Bet v 1 and to its 
soy homologue Gly m 4 being investigated by DBPCFC. 
In this multicentre trial, 82 subjects (59.4%) had positive 
DBPCFC according to harmonized evaluation criteria. 
With the aim of identifying DBPCFC positive patients 
being eligible for a follow-up trial on AIT against birch 
pollen allergen, we decided to only include patients with 
defined IgE cut off values, though being aware that IgE 
values cannot safely predict reactivity at DBPCFC [25]. 
As clinical symptoms may occur in Bet v 1 sensitized 
subjects already at first consumption of soy products 
[26], our inclusion criteria did not ask for history of clini-
cal allergy. Since no recipe was available at the planning 
stage of our trial, newly developed challenge meals were 
composed as microbiologically stable desserts based on 
powdered ingredients. Soy protein levels of active meals 
were chosen on the basis of previously published data 
[27].
Details on DBPCFC evaluation criteria used in clinical 
trials are rarely reported in the current literature and no 
consensus exists on how to discriminate positive from 
negative outcomes. Presentation of detailed evaluation 
criteria used in this trial in comparison with criteria of 
PRACTALL [8] and EuroPrevall [27] is given in Table 3.
In our DBPCFC+ patients, objective signs were most 
frequently of the mucocutaneous type. At placebo chal-
lenge, fifty percent (15/30) of all objective signs were due 
to heart rate increase and drop of blood pressure. Both 
may be symptoms of immediate type reaction but may 
as well be induced by psychovegetative factors. Thus, as 
a single parameter, neither of these cardiovascular symp-
toms seemed appropriate for identifying DBPCFC+ 
patients. Also, flush, rhinitis and conjunctivitis, possibly 
against the background of underlying atopic diseases, 
were more frequently seen in patients judged as DBP-
CFC− than in DBPCFC+ patients at placebo challenge.
Regarding subjective symptoms at DBPCFC, there is no 
consensus on how to monitor or how to score. In our trial 
as well as in a recent report [29], visual analogue scales 
(VAS), were used. We predefined cut off values for data 
analyses with regard to experiences from pain measure-
ment [23, 24]. As VAS values are prone to a certain risk of 
being unspecific, we requested a VAS value of 1.5 cm or 
more to be classified as a single positive reaction. Most of 
subjective symptoms documented in our trial were typi-
cal for contact urticaria of the oropharyngeal sites [17, 
18].
For evaluation of pollen-related food allergy with fre-
quent predominance of subjective symptoms [17, 18], 
our evaluation criteria may be more comprehensive than 
those proposed by PRACTALL [8] which neither con-
sider in detail mucocutaneous symptoms nor include 
measuring of symptom’s degree. However, we are aware 
that the complex definition of major subjective placebo 
reactions presented for this trial may not be suitable for 
routine use.
It was recently shown, that standardized food chal-
lenges are subject to a great variability in interpretation 
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Fig. 4 Cumulative dose levels of soy protein at occurrence of first signs and symptoms. Objective signs (ObjS) occurred in 58/82 (70.7%) and 
subjective symptoms (SubjS, either single or sum type) in 70/82 (85.4%) DBPCFC+ patients, respectively. SubjS to soy challenge meal started at sig‑
nificantly lower dose levels than ObjS (p < 0.001). Cumulative threshold dose eliciting objS and subjS in 50% of subjects (ED50) can be extrapolated
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of clinical symptoms [9]. Regarding placebo events, in 
the current literature, no systematic documentation in 
DBPCFC in adults, like in our trial, has been published. 
In children, objective signs and/or subjective symptoms 
occurred in at least 2.8% [12] or 12.9% [14] of challenges. 
We documented an overall number of objective placebo 
reactions in 21.6% which highlightens the complexity of 
DBPCFC evaluation.
DBPCFC is usually considered positive when objec-
tive signs occur exclusively on active and not on placebo 
challenge [8, 28, 29]. This definition is insufficient in birch 
pollen related food allergy were patients often suffer from 
subjective symptoms only and/or may present objective 
signs against their atopic background not being induced by 
DBPCFC. We suggest that minor placebo reactions should 
be compatible with positive DBPCFC outcome supposed 
that there are relevant differences between reactions at 
active and at placebo meal. With the aim of harmonization 
in a multicentre setting, we therefore suggested a defini-
tion of relevant (major) placebo reactions (Table 1).
According to theses definitions, we identified MCTD for 
subjective symptoms (0.7 g) and for objective signs (4.7 g), 
which are, however, not considered representative for 
all subjects with birch related soy allergy due to selected 
inclusion criteria. Nevertheless, data were close to those 
determined in a previous trial on soy allergy with MCTD 
of 0.9 (subjective) and 4.8 g (objective), respectively [27].
Due to our experience we feel that evaluation of DBP-
CFC outcome, only can be standardized to a certain 
extend. Final decision upon relevance of occurring sign 
and symptoms during DBPCFC still relies on the clini-
cal investigator, especially with regard to circumstances 
during the challenge procedure as well as considering 
any physical and/or psychological comorbidities of the 
patient.
Conclusions
We present a standardized approach for DBPCFC with 
soy that includes application of challenge meals with sta-
ble Gly m 4 values as well as determination of threshold 
levels in a multicentre setting. For evaluation of any treat-
ment effects on birch pollen-related food allergy, we see 
an urgent need not only for providing standardized chal-
lenge meals but also for investigating validity and reli-
ability of DBPCFC outcome scoring systems taking into 
account intensity of objective clinical signs as well as sub-
jective symptoms.
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